TROG 98.03 - Prostate - Margin +ve Post-Prostatectomy

By w.paterson
15 August, 2021
0 Comments

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

18 October, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

6 September, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $35,000

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $35,000